ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1739

Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies

Khetam Ghannam1, Marieluise Kirchner2, Holger Bang3, Thomas Häupl4, Sarah Ohrndorf1, Jan Zernicke1, Ulrike Kuckelkorn5, Philipp Mertins6, Eugen Feist7 and Gerd Burmester8, 1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, 3Orgentec Diagnostika GmbH, Mainz, Germany, 4Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 5Institute of Biochemistry, Berlin, Germany, 6Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, 7Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, 8Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany

Meeting: ACR Convergence 2023

Keywords: Anti-ACPA, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction. Given the presumed pathophysiologic role of anti-modified protein autoantibodies (AMPAs) in RA, it is important to obtain a comprehensive overview of the post-translational modified (PTM) proteins present in SF and serum of RA in order to reveal those autoantigens that might promote the expansion of autoreactive B cells. Therefore, mass spectrometry was used to identify citrullinated, carbamylated and acetylated proteins present within monomeric and IC (immune complexes) of synovial fluid (SF) and serum of RA, and serum of healthy donors (HD), which served as a control.

Methods: This study included 42 RA patients fulfilling the 2010 ACR/EULAR classification criteria, 44 patients with other arthritic diseases who served as the control group, and 47 HD. Proteins isolated from SF and serum were fractionated by sucrose gradient centrifugation and monomeric and IC IgG were isolated from the respective fractions according to protein markers. Mass spectrometry was used to identify PTMs within monomeric and IC IgG fractions. Rheumatoid factor (RF), anti-citrullinated, anti-carbamylated, and anti-acetylated antigen antibodies were analyzed by ELISA.

Results: In SF and serum of RA, positivity to anti-acetylated and anti-carbamylated IgG was restricted to samples positive for anti-cyclic citrullinated peptide (CCP) IgG. Anti- citrullinated IgG antibodies differentiated between RA and CG in serum and SF, while anti-acetylated IgG reactivities were significantly increased in RA-SF compared with CG. Monomeric and IC IgG isolated from formally seronegative RA patients showed very strong reactivity mainly against citrullinated peptides, indicating a “hidden” antibody response. Although mass spectrometry analysis identified citrullinated, carbamylated and acetylated proteins in all samples tested – SF from RA and serum from RA and HD – quality analysis revealed modified autoantigens unique to RA, and many were found in double or even triple modified isoforms. The frequency of modified carbamylated and acetylated proteins was significantly higher in RA than in HD.

Conclusion: Many RA-related autoantigens underwent single as well as multifold-modifications were identified within monomeric and IC of RA patients. Carbamylated and acetylated proteins distinguish between RA and HD. Monomers and IC isolated from formally seronegative patients showed hidden anti-citrullinated reactivities undetectable by conventional assays.


Disclosures: K. Ghannam: None; M. Kirchner: None; H. Bang: Orgentec Diagnostika GmbH, 3; T. Häupl: None; S. Ohrndorf: None; J. Zernicke: None; U. Kuckelkorn: None; P. Mertins: None; E. Feist: AbbVie, 12, has received honoraria and research grants, BMS, 12, has received honoraria and research grants, Galapagos, 12, has received honoraria and research grants, Lilly, 12, has received honoraria and research grants, MSD, 12, has received honoraria and research grants, Novartis, 12, has received honoraria and research grants, Pfizer, 12, has received honoraria and research grants, Roche, 12, has received honoraria and research grants, Sobi, 12, has received honoraria and research grants; G. Burmester: AbbVie, 2, 6, Boehringer Ingelheim, 2, 6, Bristol-Myers Squibb, 2, 6, Chugai, 6, Galapagos, 2, 6, Lilly, 2, 6, Pfizer, 2, 6, Sanofi, 2, 6.

To cite this abstract in AMA style:

Ghannam K, Kirchner M, Bang H, Häupl T, Ohrndorf S, Zernicke J, Kuckelkorn U, Mertins P, Feist E, Burmester G. Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/mass-spectrometry-identified-rheumatoid-arthritis-specific-modified-proteins-and-the-discovery-of-antigen-specific-hidden-autoantibodies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mass-spectrometry-identified-rheumatoid-arthritis-specific-modified-proteins-and-the-discovery-of-antigen-specific-hidden-autoantibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology